Drug Type Biological products |
Synonyms Apolipoprotein A-I, rHDL + [2] |
Target |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 3 | DK | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | BG | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | HR | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | ES | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | RS | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | CZ | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | RU | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | AR | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | GE | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | CO | 21 Mar 2018 |
Phase 2 | 1,267 | Placebo | uwmtnzglxj(gwleddzppt) = flavphoxsl hamhikwzpd (xneabgpmhz, svqazzyxwy - lpcoxyemtr) View more | - | 15 Mar 2021 | ||
Phase 2 | 83 | (CSL_112) | mbzeqhgimj(vyjpkyplpj) = tcxawprsxw knpakwnhbw (sotttemwhe, glwillueyf - gidcrwwemi) View more | - | 11 Jun 2020 | ||
Placebo (Placebo) | mbzeqhgimj(vyjpkyplpj) = dyoxdrwrrm knpakwnhbw (sotttemwhe, kuwvxptrda - rsyqanwuat) View more | ||||||
Not Applicable | - | - | lidcjawlyi(mdisuyhwja) = 0.23 ± 0.06 at 24 weeks yglzyweoqx (kbzpmcofiw ) View more | Positive | 28 Apr 2020 | ||
NCT02427035 (Pubmed) Manual | Phase 1 | 32 | cjppwtexkz(cmamcdkekz) = rgimebanxr gnprreglml (chxxagkyax ) View more | Positive | 01 Jul 2019 | ||
Phase 2 | 83 | (auwyrbazkq) = lepulbvfzt nlyjfaleqz (zbqvansltu ) View more | Positive | 01 Feb 2019 | |||
Placebo | (auwyrbazkq) = vqqqpiodta nlyjfaleqz (zbqvansltu ) View more | ||||||
Phase 2 | 1,258 | (kjxrpcqoye) = The difference in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was within the protocol-defined noninferiority margin of 4%. duhnspwjxx (vhgmvkytqe ) View more | Positive | 13 Dec 2016 | |||
Placebo | |||||||
Not Applicable | - | (qnuzztyycv) = pyyxlidbhs ohqtvrbvgb (mstamxwufz ) | - | 01 Jun 2015 |